Approval · Notice of Compliance 25333 · 2021
ABILIFY MAINTENA: Notice of Compliance 25333
Issued March 3, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 25333
- Date
- March 3, 2021
- Company
- Otsuka Pharmaceutical Co LtdChiyoda-Ku Tokyo, --, Japan
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Updates to the dosage and administration and action and clinical pharmacology sections of the product monograph
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ABILIFY MAINTENA | Not yet assigned | — |
Medicinal ingredients
- ARIPIPRAZOLE 300 MG per VIAL
- ARIPIPRAZOLE 400 MG per VIAL
- ARIPIPRAZOLE 300 MG per SYR
- ARIPIPRAZOLE 400 MG per SYR